Economy

Pembrolizumab fails to improve survival in head and neck squamous cell carcinoma

Pembrolizumab fails to improve survival in head and neck squamous cell carcinomaā€¯

U.S. drugs regulator the FDA gave fast-track approval for use of Keytruda for this type of cancer a year ago.

In the Phase III Keynote-040 trial, Keytruda was being investigated as a monotherapy treatment against the standard of care treatments (methotrexate, docetaxel or cetuximab). The current indication remains unchanged and clinical trials continue, including KEYNOTE-048 (ClinicalTrials.gov, NCT02358031), a phase 3 clinical trial of Keytruda in the first-line treatment of recurrent or metastatic HNSCC.

"There is significant need for new options that address the treatment gaps for patients in Europe with locally advanced or metastatic urothelial carcinoma, especially for those who have failed on prior platinum treatment or are ineligible for cisplatin-containing chemotherapy", noted Dr Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories.

At the same time that Merck announced the results of its Keynote-040 study, Bristol said the Food and Drug Administration had accepted its application to have Keytruda's rival, Opdivo, dosed at 480-milligrams every four weeks for 30 minutes. Patients enrolled in the study had been previously treated with 1-2 platinum-containing systemic regimens.

Keytruda (pembrolizumab) monotherapy failed to significantly improve overall survival (OS) compared to standard of care in the KEYNOTE-040 trial, which enrolled almost 500 participants with HNSCC who hadn't adequately responded to one or more platinum-containing systemic treatments. Dansey said the company will share the trial data at an upcoming conference, but did not specify which one.

Head and neck cancer is a catch-all for various cancers that develop in or around the throat, larynx, nose, sinuses and mouth.

The Keytruda clinical development program includes more than 30 tumor types in more than 500 clinical trials, including more than 300 trials that combine Keytruda with other cancer treatments. Earlier this month, Keytruda trials in the blood cancer multiple myeloma were stopped due to more deaths among those who received Keytruda along with standard combination therapy than those on standard treatment alone. In the trials, Keytruda was being tested in combination with drugs developed by Celgene (CELG), including Pomalyst and Revlimid.

It is a second rare setback for the medicine seen as the leading treatment among immunotherapies from the same class, known as PD-1 or PD-L1 inhibitors.

The pivotal phase 3 trial created to evaluate pembrolizumab for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma failed to meet its prespecified primary endpoint of OS, according to the drug's manufacturer. The designation was granted based on Phase III data that showed the drug succeeded in its endpoint of overall survival - the same endpoint that Merck's drug failed to hit.



Like this

Latest


26 July 2017
Republicans moving to repeal financial rule opposed by banks
Before this year, CRA had been successfully used only once, in 2001, to overturn a Clinton-era rule on ergonomic standards. The specific issue involves mandatory arbitration clauses in contracts between consumers and financial institutions.

26 July 2017
Tallahassee Ranked In The Top 10 For Most Educated Cities
The Detroit-Warren-Dearborn area came in at number 78 on the list, beating out other cities like Los Angeles and Toledo. The region ranked 32nd for its educational attainment and 69th for its quality of education and attainment gap.

26 July 2017
Suns G Brandon Knight suffers torn ACL
It looked like there was a path for Knight to bounce back this season, but the injury derailed any chances to do that. Last season, Knight averaged just 11.0 points per game, a career low, in 54 appearances - 49 of them off the bench.

26 July 2017
Temple Mount crisis: Israel decides to remove metal detectors
Israel has denied it has a hidden agenda, portraying the metal detectors as a needed means to prevent attacks. Mourners accompanied Mohammed Jawawdeh's coffin from Wihdat city, home to a large Palestinian refugee camp.

26 July 2017
Putin, Iraqi Vice President Maliki Meet Near St. Petersburg
Putin said during the talks that Moscow and Baghdad "have a great deal yet to do" to strengthen bilateral economic cooperation.

26 July 2017
Missing RCMP grenade launcher has been found
Mounties said a member of the public found the equipment near where they believed it went missing. An investigation into how the gun and ammunition went missing in the first place is continuing.

26 July 2017
Jaguars lock up Brandon Linder with five-year extension
Jaguars OL Brandon Linder has signed a five-year contract extension to stay with the team through 2022, the club announced today. Linder worked at right guard early in the off-season program before moving back to center. "It means the world", Linder said.

26 July 2017
Several injured in crash involving bus and pickup
There were 20 people on the bus and one person in the pickup, according to Chief Art Groux, of Suffield Ambulance. Mountain Road was closed between North Stone Street and Phelps Road for several hours and reopened around 10 a.m.

26 July 2017
Israel just blocked 3 Jews from entering because they support BDS
This is believed to be the first time that Jews have been denied entry to Israel due to their political opinions. Three of the five are JVP members, an organization that promotes human rights for Palestinians.

26 July 2017
Cardinals bring up Bader as Fowler hits the DL
Fowler, who was batting third in the lineup before suffering the injury, joined teammate Stephen Piscotty (groin) on the shelf. He took a major step forward in the Arizona Fall League a year ago , batting.304 and driving in 16 runs over 21 games.



Recommended